-
Published25/11/2024
-
Today03/12/2024
-
Deadline11/12/2024
-
Opening of tenders11/12/2024
Utilities
- indicates text translated automatically in your browsing language
The drug program Immunoglobulinum humanum and RDTL Baricitinibum Text automatically translated in your browsing language Automatically translated
The subject-matter of the contract is: The drug program Immunoglobulinum humanum and RDTL Baricitinibum 1. OPTION – YES – The contracting authority provides for the option to be exercised. The type and maximum value of the option and the circumstances in which the option is exercised are described in Annex 1 and Annex 3 to this SWZ. 2. The requirements relating to the subject-matter of the contract and the conditions for implementation are set out in the annexes to the draft contract Annex 1 Annex 2 Tender form Annex 3/1-3/2 Price calculation – description of the subject-matter of the contract 3. Common Procurement Vocabulary (CPV) code: 33600000-6 Medicinal products Text automatically translated in your browsing language Automatically translated
https://usdk.eb2b.com.pl/
https://usdk.eb2b.com.pl/
This content published on this page is meant purely as an additional service and has no legal effect. The Union's institutions do not assume any liability for its contents. The official versions of the relevant tendering notices are those published in the Supplement of Official Journal of the European Union and available in TED. Those official texts are directly accessible through the links embedded in this page. For more information please see Public Procurement Explainability and Liability notice.